SCHEMBL20587606

SCHEMBL20587606

O=C(N/N=C\c1cc(Cl)ccc1O)c1cc(F)cc(F)c1

nearest known ligand 0.72

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM1A O60341 4/20 0.72
KMT2A Q03164 6/20 0.69
RAB9A P51151 6/20 0.69
MEN1 O00255 5/20 0.69
NPC1 O15118 5/20 0.69
KDM4E B2RXH2 4/20 0.69
HTT P42858 4/20 0.69
SMN1; SMN2 Q16637 4/20 0.69
LMNA P02545 2/20 0.69
MITF O75030 2/20 0.69
PSMD14 O00487 1/20 0.69
POLB P06746 1/20 0.69
MMP2 P08253 1/20 0.69
BLM P54132 1/20 0.69
GPR174 Q9BXC1 1/20 0.69
L3MBTL1 Q9Y468 1/20 0.69
KLF5 Q13887 1/20 0.63
MAPT P10636 4/20 0.59
PIK3CG P48736 1/20 0.59
CYP1A2 P05177 1/20 0.59

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20587607 1.00 KDM1A (0.72) KDM1AKMT2ARAB9AMEN1NPC1
SCHEMBL684783 0.91 KDM1A (0.82) KDM1AKMT2ARAB9AMEN1NPC1
SCHEMBL684998 0.89 RAB9A (0.76) KDM1AKMT2ARAB9AMEN1NPC1
SCHEMBL14907005 0.86 KDM1A (0.76) KDM1AKMT2ARAB9AMEN1NPC1
SCHEMBL683818 0.86 KDM1A (0.89) KDM1AKMT2ARAB9AMEN1NPC1
SCHEMBL6568344 0.86 KDM1A (0.89) KDM1AKMT2ARAB9AMEN1NPC1
SCHEMBL6568342 0.86 KDM1A (0.89) KDM1AKMT2ARAB9AMEN1NPC1
SCHEMBL20588144 0.84 KMT2A (0.81) KDM1AKMT2ARAB9AMEN1NPC1
SCHEMBL20588146 0.84 KMT2A (0.81) KDM1AKMT2ARAB9AMEN1NPC1
SCHEMBL684605 0.84 KDM1A (0.72) KDM1AKMT2ARAB9AMEN1NPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12325678-B2 Anti-fungals compounds targeting the synthesis of fungal sphingolipids THE RESEARCH FOUNDATION FOR THE STATE UNIVERSITY OF NEW YORK (US) 2025-06-10 US disclosed
US-20240124392-A1 ANTI-FUNGALS COMPOUNDS TARGETING THE SYNTHESIS OF FUNGAL SPHINGOLIPIDS THE RESEARCH FOUNDATION FOR THE STATE UNIVERSITY OF NEW YORK (US) 2024-04-18 US disclosed
US-11858880-B2 Anti-fungals compounds targeting the synthesis of fungal sphingolipids THE RESEARCH FOUNDATION FOR THE STATE UNIVERSITY OF NEW YORK (US) 2024-01-02 US disclosed
US-20220394973-A1 ANTI-FUNGALS COMPOUNDS TARGETING THE SYNTHESIS OF FUNGAL SPHINGOLIPIDS THE RESEARCH FOUNDATION FOR THE STATE UNIVERSITY OF NEW YORK (US) 2022-12-15 US disclosed
US-11414378-B2 Anti-fungals compounds targeting the synthesis of fungal sphingolipids THE RESEARCH FOUNDATION FOR THE STATE UNIVERSITY OF NEW YORK (US) 2022-08-16 US disclosed
US-20200207705-A1 ANTI-FUNGALS COMPOUNDS TARGETING THE SYNTHESIS OF FUNGAL SPHINGOLIPIDS THE RESEARCH FOUNDATION FOR THE STATE UNIVERSITY OF NEW YORK (US) 2020-07-02 US disclosed
EP-3638649-A1 ANTI-FUNGALS COMPOUNDS TARGETING THE SYNTHESIS OF FUNGAL SPHINGOLIPIDS The Research Foundation for The State University of New York (US) 2020-04-22 EP disclosed
WO-2018232298-A1 ANTI-FUNGALS COMPOUNDS TARGETING THE SYNTHESIS OF FUNGAL SPHINGOLIPIDS THE RESEARCH FOUNDATION FOR THE STATE UNIVERSITY OF NEW YORK (US) 2018-12-20 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220394973-A1 ANTI-FUNGALS COMPOUNDS TARGETING THE SYNTHESIS OF FUNGAL SPHINGOLIPIDS ERG28, UGCG, DPM1 KDM1A 2352/4885KMT2A 3071/4885RAB9A 1994/4885
US-12325678-B2 Anti-fungals compounds targeting the synthesis of fungal sphingolipids ERG28, UGCG, SMPD1 KDM1A 2058/4885KMT2A 2770/4885RAB9A 2101/4885
US-20200207705-A1 ANTI-FUNGALS COMPOUNDS TARGETING THE SYNTHESIS OF FUNGAL SPHINGOLIPIDS ERG28, UGCG, DPM1 KDM1A 2352/4885KMT2A 3071/4885RAB9A 1994/4885
US-11858880-B2 Anti-fungals compounds targeting the synthesis of fungal sphingolipids ERG28, UGCG, DPM1 KDM1A 2352/4885KMT2A 3071/4885RAB9A 1994/4885
US-20240124392-A1 ANTI-FUNGALS COMPOUNDS TARGETING THE SYNTHESIS OF FUNGAL SPHINGOLIPIDS ERG28, UGCG, DPM1 KDM1A 2352/4885KMT2A 3071/4885RAB9A 1994/4885
US-11414378-B2 Anti-fungals compounds targeting the synthesis of fungal sphingolipids ERG28, UGCG, LSS KDM1A 1705/4885KMT2A 2523/4885RAB9A 2178/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.